Compare LTC Properties Inc (LTC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? LTC Properties Inc trades at $43.09 (market cap $2.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: LTC Properties Inc is far larger — about 2.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and LTC Properties Inc pays a 5.31% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 89 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LTC | MRVI | |
|---|---|---|
Market Cap | $2.31B | $972.90M |
Volume | 323,404 | 4,325,710 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $9.00 |
52-Week Low | $34.04 | $2.83 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $3.05B | $1.08B |
Dividend Yield | 5.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $43.20, up 0.35% with a bullish technical signal and strong fundamental metrics including 38.93% net income margin and 12.11% ROE. Recent acquisitions totaling $360 million accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Revenue growth continues with 2025 revenue reaching $263 million, though profit margins have moderated from historical highs.
The outlook remains positive with analyst consensus target of $49.67 representing 15% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in portfolio transformation. The stock offers balanced risk-reward with income generation and growth potential from strategic acquisitions in the seniors housing sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
